Ms.barry

Biography

An experienced physician specializing in adult infectious diseases and a seasoned executive with experience at both large pharma and small biotech companies, Dr. Hafkin brings the deep understanding of unmet medical needs facing patients and doctors dealing with life-threatening infections. Prior to MicuRx Pharmaceuticals, Dr. Hafkin served in executive roles at Nobelex, Affinium Pharmaceuticals (acquired by Debiopharm Group™), Cumbre Pharmaceuticals and Advancis Pharmaceuticals, where he was responsible for all aspects of pharmaceutical development, registration and marketing support. Prior to Advancis, he served as director of virology and immunology at Boehringer Ingelheim where he built the clinical trials team in virology and managed development for Aptivus® (tipranivir). Previously, he served as senior director and therapeutic area director for infectious diseases at Pharmacia where he led the global development of blockbuster agents Zyvox® (linezolid). Prior to Pharmacia, Dr. Hafkin maintained an infectious disease and epidemiology practice. He also served as a principal investigator for the Epidemic Intelligence Service of the Centers for Disease Control. He received his M.D. from the University of Texas Medical School in San Antonio and completed his infectious disease fellowship at Stanford University Medical Center.    

Research Interest

An experienced physician specializing in adult infectious diseases and a seasoned executive with experience at both large pharma and small biotech companies, Dr. Hafkin brings the deep understanding of unmet medical needs facing patients and doctors dealing with life-threatening infections. Prior to MicuRx Pharmaceuticals, Dr. Hafkin served in executive roles at Nobelex, Affinium Pharmaceuticals (acquired by Debiopharm Group™), Cumbre Pharmaceuticals and Advancis Pharmaceuticals, where he was responsible for all aspects of pharmaceutical development, registration and marketing support. Prior to Advancis, he served as director of virology and immunology at Boehringer Ingelheim where he built the clinical trials team in virology and managed development for Aptivus® (tipranivir). Previously, he served as senior director and therapeutic area director for infectious diseases at Pharmacia where he led the global development of blockbuster agents Zyvox® (linezolid). Prior to Pharmacia, Dr. Hafkin maintained an infectious disease and epidemiology practice. He also served as a principal investigator for the Epidemic Intelligence Service of the Centers for Disease Control. He received his M.D. from the University of Texas Medical School in San Antonio and completed his infectious disease fellowship at Stanford University Medical Center.